California's Stem Cell and Gene Therapy Agency Troubled by Morale Problems, Pay Inequality and More, Says Audit
CIRM also was a laggard in work on three-year-old audit recommendations
The $12 billion California stem cell agency is suffering from a wide array of afflictions, ranging from employee morale problems and an excessively large governing board to pay inequity and royalty income issues, according to the agency’s latest performance…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.